From clinical trial results to major drug approvals, here we present an overview of the latest industry news from the biggest players in oncology.
Merck has extended its all-important lung-cancer lead, after combination Phase III trial demonstrates that Keytruda extends lung cancer survival.
In this article from Future Oncology, the author considers the data supporting the sequential use of available EGFR TKIs and key considerations for selection of first-line treatment.
How do factors such as night work and light-at-night exposure increase a woman’s breast cancer risk? Find out in this editorial from Breast Cancer Management.